ReviewWorld journal of gastroenterology2013
What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?
Review in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- Association between hypertension and nonalcoholic fatty liver disease: a cross-sectional and meta-analysis study.Journal of human hypertension · 2023Pooled it
- Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease.Frontiers in medicine · 2021Pooled it
- Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology.Obesity surgery · 2015Pooled it
- Article
- Blood Pressure Trajectories in Young Adulthood and Midlife Steatotic Liver Disease.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms and Clinical Implications-A Narrative Review.International journal of molecular sciences · 2026Review
- Adiponectin as a Predictor of Metabolic Dysfunction-Associated Steatotic Liver Disease and Non-Alcoholic Fatty Liver Disease: A 17-Year Korean Cohort Study.Diabetes & metabolism journal · 2026Article
- Associations Between Triglycerides and Walking Capacity in Community-Dwelling Older Adults with Metabolic Syndrome.Diseases (Basel, Switzerland) · 2026Article
- Review
- Text phrase-mining in identifying and classifying maternal proteins and genes across preeclampsia and similar pathologies.Physiological reports · 2025Article
- Mapping Obesity Trends in Saudi Arabia: A Four-Year Description Study.Healthcare (Basel, Switzerland) · 2024Article
- Adipokines in the Crosstalk between Adipose Tissues and Other Organs: Implications in Cardiometabolic Diseases.Biomedicines · 2024Review
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?Lipids in health and disease · 2024Review
- Could Adverse Effects of Antibiotics Due to Their Use/Misuse Be Linked to Some Mechanisms Related to Nonalcoholic Fatty Liver Disease?International journal of molecular sciences · 2024Review
- The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression.Nutrients · 2023Review
- Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.World journal of hepatology · 2023Review
- Factors related to hypermetabolism in individuals with type 2 diabetes mellitus and non-alcoholic fatty liver disease.Scientific reports · 2023Article
- Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.Nature reviews. Endocrinology · 2022Review
- Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease.Chinese journal of integrative medicine · 2022Article
- Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation.Antioxidants (Basel, Switzerland) · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is recognized as the most common type of chronic liver disease in Western countries. Insulin resistance is a key factor in the pathogenesis of NAFLD, the latter being considered as the hepatic component of insulin resistance or obesity. Adiponectin is the most abundant adipose-specific adipokine. There is evidence that adiponectin decreases hepatic and systematic insulin resistance, and attenuates liver inflammation and fibrosis. Adiponectin generally predicts steatosis grade and the severity of NAFLD; however, to what extent this is a direct effect or related to the presence of more severe insulin resistance or obesity remains to be addressed. Although there is no proven pharmacotherapy for the treatment of NAFLD, recent therapeutic strategies have focused on the indirect upregulation of adiponectin through the administration of various therapeutic agents and/or lifestyle modifications. In this adiponectin-focused review, the pathogenetic role and the potential therapeutic benefits of adiponectin in NAFLD are analyzed systematically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.